- Home
- ATYR vs TCRX Comparison
ATYR vs TCRX Comparison
Compare ATYR & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATYR
- TCRX
- Stock Information
- Founded
- ATYR 2005
- TCRX 2018
- Country
- ATYR United States
- TCRX United States
- Employees
- ATYR N/A
- TCRX N/A
- Industry
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- ATYR Health Care
- TCRX Health Care
- Exchange
- ATYR Nasdaq
- TCRX Nasdaq
- Market Cap
- ATYR 535.0M
- TCRX 91.7M
- IPO Year
- ATYR 2015
- TCRX 2021
- Fundamental
- Price
- ATYR $1.03
- TCRX $1.71
- Analyst Decision
- ATYR Strong Buy
- TCRX Strong Buy
- Analyst Count
- ATYR 5
- TCRX 5
- Target Price
- ATYR $23.25
- TCRX $9.40
- AVG Volume (30 Days)
- ATYR 4.9M
- TCRX 215.6K
- Earning Date
- ATYR 11-06-2025
- TCRX 11-11-2025
- Dividend Yield
- ATYR N/A
- TCRX N/A
- EPS Growth
- ATYR N/A
- TCRX N/A
- EPS
- ATYR N/A
- TCRX N/A
- Revenue
- ATYR N/A
- TCRX $6,961,000.00
- Revenue This Year
- ATYR $478.72
- TCRX $255.18
- Revenue Next Year
- ATYR $1,899.26
- TCRX N/A
- P/E Ratio
- ATYR N/A
- TCRX N/A
- Revenue Growth
- ATYR N/A
- TCRX N/A
- 52 Week Low
- ATYR $1.67
- TCRX $1.02
- 52 Week High
- ATYR $7.29
- TCRX $6.23
- Technical
- Relative Strength Index (RSI)
- ATYR 21.81
- TCRX 42.35
- Support Level
- ATYR $5.08
- TCRX $1.73
- Resistance Level
- ATYR $6.50
- TCRX $1.96
- Average True Range (ATR)
- ATYR 0.47
- TCRX 0.11
- MACD
- ATYR -0.25
- TCRX -0.02
- Stochastic Oscillator
- ATYR 0.82
- TCRX 16.67
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.